<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637910</url>
  </required_header>
  <id_info>
    <org_study_id>FARM6F5JER</org_study_id>
    <secondary_id>2007-004786-17</secondary_id>
    <nct_id>NCT00637910</nct_id>
  </id_info>
  <brief_title>Tarceva Italian Lung Optimization tRial</brief_title>
  <acronym>TAILOR</acronym>
  <official_title>Optimization of Erlotinib for the Treatment of Patients With Advanced Non Small Cell Lung Cancer: an Italian Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fatebenefratelli and Ophthalmic Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Niguarda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fatebenefratelli and Ophthalmic Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the superiority of docetaxel in comparison to erlotinib in
      second line in wild-type EGFR tumour patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Erlotinib is registered in all patients affected with NSCLC in second and subsequent lines
      with a small benefit on Overall Survival. Recent evidence suggest that patients with EGFR
      mutations have a clear benefit when they are treated with EGFR tyrosine kinase inhibitors,
      while the role of these drugs in wild-type EGFR patients, that are representing the large
      majority (about 85-90%), is still unclear and no properly planned trials assessed before this
      issue. Recently, indirect evidence on subgroup analyses on randomized trial suggest that
      chemotherapy might be superior to erlotinib in wild-type EGFR patients.

      Moreover, several authors do not recommend the use of EGFR determined with
      immunohistochemistry (IHC) or FISH because they do not reproducibly predict outcome.

      For these reasons the protocol was amended in May 2011 in a superiority trial of docetaxel
      versus erlotinib, while the first version was aimed to assess the interaction with
      biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months after the last patient is randomized</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>with 4 years and 12 months after the last patient is randomized</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response assessed with RECIST criteria</measure>
    <time_frame>within 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed with QLQ-C30 and QLQ-LC13 questionnaires</measure>
    <time_frame>within 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity, graded according to the NCI-CTAE version 3.0</measure>
    <time_frame>within 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and nature of serious adverse reactions</measure>
    <time_frame>within 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature withdrawals</measure>
    <time_frame>within 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Non Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Erlotinib Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops</description>
    <arm_group_label>Erlotinib Arm</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops</description>
    <arm_group_label>Docetaxel Arm</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Histological or cytological confirmation of NSCLC (may be from initial diagnosis of
             NSCLC or subsequent biopsy). Only patients with available tissue samples may be
             included in the study

          -  Absence of EGFR mutations of exons 19 or 21 (randomization)

          -  Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy

          -  One prior platinum-based at adequate doses and taxane free regimen

          -  Measurable (uni-dimensional) disease by RECIST in a lesion not previously irradiated
             or non-measurable disease

          -  ECOG-PS 0-2

          -  ANC greater than 1.5 x 109/L and platelets greater than 100 x 109/L

          -  Bilirubin level either normal or &lt;1.5xULN

          -  AST (SGOT) and ALT (SGPT) &lt;2.5xULN (â‰¤5 x ULN if liver metastases are present)

          -  Serum creatinine &lt;1.5xULN

          -  Effective contraception for both, male and female pts, if the risk of conception
             exists

          -  Recovery from all acute toxicities of prior therapies

          -  Provision of written informed consent to the analysis of biological markers
             (registration)

          -  Provision of written informed consent to enter the randomized part of the study
             (randomization)

        Exclusion Criteria:

          -  Prior therapy with an experimental agent whose primary mechanism of action is
             inhibition of EGFR or its associated tyrosine kinase

          -  Prior chemotherapy with taxanes

          -  Newly diagnosed CNS metastases that have not yet been treated with surgery and/or
             radiation. Pts with previously diagnosed and treated CNS metastases or spinal cord
             compression may be considered if they have evidence of clinically SD (no steroid
             therapy or steroid dose being tapered) for at least 28 daysLess than 14 days since
             completion of prior radiotherapy or persistence of any radiotherapy related toxicity

          -  Any unresolved chronic toxicity from previous anticancer therapy that, in the opinion
             of the investigator, makes it inappropriate for the patient to be enrolled in the
             study Known severe hypersensitivity to erlotinib or any of the excipients of this
             product

          -  Known hypersensitivity to docetaxel, polysorbate 80 or other drugs formulated with
             polysorbate 80, or any of the excipients of docetaxel

          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with
             the exception of basal cell carcinoma or cervical cancer in situ

          -  Unable to swallow tablets

          -  Any evidence of clinically active interstitial lung disease (patients with chronic,
             stable, radiographic changes who are asymptomatic or patients with uncomplicated
             progressive lymphangitic carcinomatosis need not be excluded)

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (e.g., unstable or uncompensated respiratory, cardiac, hepatic or renal disease)

          -  As judged by the investigator, any inflammatory changes of the surface of the eye

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the patient to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Scanni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fatebenefratelli and Ophthalmic Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina C Garassino, MD</last_name>
    <phone>+39 0263632223</phone>
    <email>marina.garassino@fbf.milano.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Serena Girelli, Biologist</last_name>
    <phone>+39 0263632223</phone>
    <email>datamanager@fbf.milano.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Civili Riuniti Giovanni Paolo II</name>
      <address>
        <city>Sciacca</city>
        <state>Agrigento</state>
        <zip>92100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Fabriano Hospital</name>
      <address>
        <city>Fabriano</city>
        <state>Ancona</state>
        <zip>60044</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Umberto I - Lancisi - Salesi</name>
      <address>
        <city>Torrette</city>
        <state>Ancona</state>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oncologia A.S.L. AV1</name>
      <address>
        <city>Ariano Irpino</city>
        <state>Avellino</state>
        <zip>83031</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Pesenti-Fenaroli Hospital</name>
      <address>
        <city>Alzano Lombardo</city>
        <state>Bergamo</state>
        <zip>24022</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Nastasi, MD</last_name>
      <phone>+39 0354177235</phone>
      <email>giuseppe.nastasi@bolognini.bg.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Nastasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Vipiteno</name>
      <address>
        <city>Vipiteno</city>
        <state>Bolzano</state>
        <zip>39049</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Azienda Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Ferrari, MD</last_name>
      <phone>+39 0303996583</phone>
      <email>bscivile@numerica.it</email>
    </contact>
    <investigator>
      <last_name>Vittorio Ferrari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pneumologia Azienda Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Ferrari, MD</last_name>
      <phone>+39 0303996583</phone>
      <email>bscivile@numerica.it</email>
    </contact>
    <investigator>
      <last_name>Vittorio Ferrari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale centrale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <state>BZ</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuela Vattemi, MD</last_name>
      <phone>+39 0471908952</phone>
      <email>emanuela.vattemi@asbz.it</email>
    </contact>
    <investigator>
      <last_name>Emanuela Vattemi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario di Monserrato</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Massidda, MD</last_name>
      <phone>+39 07051096208</phone>
      <email>masbru@pacs.unica.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Massidda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Barbara</name>
      <address>
        <city>Iglesias</city>
        <state>Carbonia Iglesias</state>
        <zip>09016</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Renzetti Hospital</name>
      <address>
        <city>Lanciano</city>
        <state>Chieti</state>
        <zip>66034</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Nuzzo, MD</last_name>
      <phone>+39 0872706220</phone>
      <email>nuzzo@oncologialanciano.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Nuzzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Elia</name>
      <address>
        <city>Caltanissetta</city>
        <state>CL</state>
        <zip>93100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>San Francesco Hospital</name>
      <address>
        <city>Paola</city>
        <state>Cosenza</state>
        <zip>87027</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Saluzzo Savigliano</name>
      <address>
        <city>Saluzzo</city>
        <state>Cuneo</state>
        <zip>12037</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Istituto Toscano Tumori Ospedale S. Giuseppe Antica Sede</name>
      <address>
        <city>Empoli</city>
        <state>Firenze</state>
        <zip>50053</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianmaria Fiorentini, MD</last_name>
      <phone>+39 0571702284</phone>
      <email>oncologiaempoli@usl11.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Gianmaria Fiorentini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monfalcone Hospital</name>
      <address>
        <city>Monfalcone</city>
        <state>Gorizia</state>
        <zip>34074</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Ferrari</name>
      <address>
        <city>Casarano</city>
        <state>Lecce</state>
        <zip>73042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Casalpusterlengo</name>
      <address>
        <city>Casalpusterlengo</city>
        <state>Lodi</state>
        <zip>26841</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria Goretti</name>
      <address>
        <city>Latina</city>
        <state>LT</state>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>B. Eustachio Hospital</name>
      <address>
        <city>San Severino Marche</city>
        <state>Macerata</state>
        <zip>62027</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>San Vincenzo Hospital</name>
      <address>
        <city>Taormina</city>
        <state>Messina</state>
        <zip>98039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Ferrau, MD</last_name>
      <phone>+39 0942579322331</phone>
      <email>omtaormina@tin.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Ferrau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Melegnano- P.O. Gorgonzola</name>
      <address>
        <city>Gorgonzola</city>
        <state>Milano</state>
        <zip>20069</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano Isa, MD</last_name>
      <phone>+39 0295707207</phone>
      <email>luciano.isa@tiscalinet.it</email>
    </contact>
    <investigator>
      <last_name>Luciano Isa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legnano Hospital</name>
      <address>
        <city>Legnano</city>
        <state>Milano</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giambattista Roda, MD</last_name>
      <phone>+39 0331449306</phone>
      <email>laelena75@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Gianbattista Roda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Legnano -Presidio di Magenta</name>
      <address>
        <city>Magenta</city>
        <state>Milano</state>
        <zip>20013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rho Hospital - Azienda Ospedaliera Salvini-Garbagnate</name>
      <address>
        <city>Rho</city>
        <state>Milano</state>
        <zip>20017</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Multimedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>Milano</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ornella Gottardi, MD</last_name>
      <phone>+39 02 24209498</phone>
      <email>ornella.gottardi@multimedica.it</email>
    </contact>
    <investigator>
      <last_name>Ornella Gottardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Vimercate</name>
      <address>
        <city>Vimercate</city>
        <state>Milano</state>
        <zip>20059</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Fagnani, MD</last_name>
      <phone>+39 0362383230</phone>
      <email>daniele.fagnani@libero.it</email>
    </contact>
    <investigator>
      <last_name>Daniele Fagnani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vizzolo Predabissi Hospital</name>
      <address>
        <city>Vizzolo Predabissi</city>
        <state>Milano</state>
        <zip>20070</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>San Leonardo Hospital</name>
      <address>
        <city>Gragnano</city>
        <state>Napoli</state>
        <zip>80054</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Vigevano</name>
      <address>
        <city>Vigevano</city>
        <state>Pavia</state>
        <zip>27029</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Palermo</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Palmeri, MD</last_name>
      <phone>+39 0916552506</phone>
      <email>sergiopalmeri@alice.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Palmeri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Massimo Hospital</name>
      <address>
        <city>Penne</city>
        <state>Pescara</state>
        <zip>65017</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Umberto I Hospital</name>
      <address>
        <city>Lugo</city>
        <state>Ravenna</state>
        <zip>48022</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Cruciani, MD</last_name>
      <phone>+39 0545214081</phone>
      <email>g.cruciani@ausl.ra.it</email>
    </contact>
    <investigator>
      <last_name>Giorgio Cruciani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Siderno - ASL nÂ°9 Locri</name>
      <address>
        <city>Siderno</city>
        <state>Reggio Calabria</state>
        <zip>89946</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>S. Sebastiano Hospital</name>
      <address>
        <city>Correggio</city>
        <state>Reggio Emilia</state>
        <zip>42015</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Zoboli, MD</last_name>
      <phone>+39 0522 630111</phone>
      <email>zobolia@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Zoboli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Scandiano</name>
      <address>
        <city>Scandiano</city>
        <state>Reggio Emilia</state>
        <zip>42019</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>S. Giovanni Evangelista Hospital</name>
      <address>
        <city>Tivoli</city>
        <state>Roma</state>
        <zip>00019</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Spremberg, MD</last_name>
      <phone>+39 07743164353</phone>
      <email>franco.spremberg@libero.it</email>
    </contact>
    <investigator>
      <last_name>Franco Spremberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL SA1 -P.O. Umberto I</name>
      <address>
        <city>Nocera Inferiore</city>
        <state>Salerno</state>
        <zip>84014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Grimaldi, MD</last_name>
      <phone>+39 0819213331</phone>
      <email>gsgrimaldi@fastwebnet.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Grimaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero San Luca</name>
      <address>
        <city>Vallo della Lucania</city>
        <state>Salerno</state>
        <zip>84078</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Valdichiana &quot;Nottola&quot;</name>
      <address>
        <city>Montepulciano</city>
        <state>Siena</state>
        <zip>53045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Crispino, MD</last_name>
      <phone>+39 0578713111</phone>
      <email>dip.oncologico@usl7.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Crispino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Valdelsa &quot;Campostaggia&quot;</name>
      <address>
        <city>Poggibonsi</city>
        <state>Siena</state>
        <zip>53036</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Crispino, MD</last_name>
      <phone>+39 0577586927</phone>
      <email>s.crispino@usl7.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Crispino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Terni</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fausto Roila, MD</last_name>
      <phone>+39 0744205584</phone>
      <email>roila.fausto@libero.it</email>
    </contact>
    <investigator>
      <last_name>Fausto Roila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multimedia Santa Maria</name>
      <address>
        <city>Castellanza</city>
        <state>Varese</state>
        <zip>21053</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ornella Gottardi, MD</last_name>
      <phone>+39 0331476111</phone>
      <email>ornella.gottardi@multimedica.it</email>
    </contact>
    <investigator>
      <last_name>Ornella Gottardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Busto Arsizio</name>
      <address>
        <city>Saronno</city>
        <state>Varese</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Verusio, MD</last_name>
      <phone>+39 029613576</phone>
      <email>cverusio@aobusto.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Verusio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Umberto I Hospital</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis</name>
      <address>
        <city>Legnago</city>
        <state>Verona</state>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bonetti, MD</last_name>
      <phone>0039.0442632418</phone>
      <email>andrea.bonetti@aulsslegnago.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Bonetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>S. Giovanni di Dio Hospital</name>
      <address>
        <city>Agrigento</city>
        <zip>92100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Donato</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Consorziale Policlinico</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fatebenefratelli Hospital</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>G. Rummo Hospital</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Daniele, MD</last_name>
      <phone>+39 082457724</phone>
      <email>bruno.daniele@ao-rummo.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Daniele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Labianca, MD</last_name>
      <phone>+39 035 269724859</phone>
      <email>rlabian@tin.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Labianca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Armando Businco Oncological Hospital</name>
      <address>
        <city>Cagliari</city>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efisio Defraia, MD</last_name>
      <phone>+39 0706095332</phone>
      <email>defraiae@alice.it</email>
    </contact>
    <investigator>
      <last_name>Efisio Defraia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Cardarelli ASL 3</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Sant'Anna Hospital</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mariano Santo Hospital</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore di Crema</name>
      <address>
        <city>Crema</city>
        <zip>26013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>S. Croce e Carle Hospital</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Colantonio, MD</last_name>
      <phone>+39 0171616739</phone>
      <email>i.colantonio@libero.it</email>
    </contact>
    <investigator>
      <last_name>Ida Colantonio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. S. Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50130</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50130</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>A.O. San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Galliera Hospital</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Decensi, MD</last_name>
      <phone>+39 010 5634501</phone>
      <email>andrea.decensi@galliera.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Decensi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>F. Veneziale Hospital</name>
      <address>
        <city>Isernia</city>
        <zip>86170</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liberato Di Lullo, MD</last_name>
      <phone>+39 0865442212</phone>
      <email>oncologia.is@infinito.it</email>
    </contact>
    <investigator>
      <last_name>Liberato Di Lullo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Lecco</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Ardizzoia, MD</last_name>
      <phone>+39 0341489900</phone>
      <email>antonio.ardizoia@tin.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Ardizzoia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fatebenefratelli and Ophthalmic Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella Farina, MD</last_name>
      <phone>+39 0263632223</phone>
      <email>gabriella.farina@fbf.milano.it</email>
    </contact>
    <contact_backup>
      <last_name>Marina C Garassino, MD</last_name>
      <phone>+39 0263632223</phone>
      <email>marina.garassino@fbf.milano.it</email>
    </contact_backup>
    <investigator>
      <last_name>Gabriella Farina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Ospedale Maggiore Policlinico - Mangiagalli e Regina Elena</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Tomirotti, MD</last_name>
      <phone>+39 0255034670</phone>
      <email>mtomirotti@policlinico.mi.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Tomirotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Paolo Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Foa, MD</last_name>
      <phone>+39 0250323085</phone>
      <email>paolo.foa@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Foa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Carlo Borromeo Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cristina Locatelli, MD</last_name>
      <phone>+39 0240222270</phone>
      <email>locatellimc@hotmail.com;</email>
    </contact>
    <investigator>
      <last_name>Maria Cristina Locatelli Locatelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Luigi Sacco Polo Universitario</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Piazza, MD</last_name>
      <phone>+39 0239042493</phone>
      <email>e.piazza@hsacco.it</email>
    </contact>
    <investigator>
      <last_name>Elena Piazza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Monaldi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Cardarelli Hospital</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>D. Cotugno Hospital</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>San Gennaro Hospital - ASL NA 1</name>
      <address>
        <city>Napoli</city>
        <zip>80136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della CaritÃ </name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Alabiso, MD</last_name>
      <phone>+39 03213733984</phone>
      <email>alabiso@med.unipmn.it</email>
    </contact>
    <investigator>
      <last_name>Oscar Alabiso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Presidio &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero &quot;M. Ascoli&quot; ARNAS Civico</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico &quot;La Maddalena&quot;</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>S. Maria della Misericordia Hospital</name>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Piacenza Hospital</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Cavanna, MD</last_name>
      <phone>+39 0523302697</phone>
      <email>l.cavanna@ausl.pc.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Cavanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S. Maria degli Angeli Hospital</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Tumolo, MD</last_name>
      <phone>+39 0434399464</phone>
      <email>salvatore.tumolo@aopn.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Salvatore Tumolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Cruciani, MD</last_name>
      <phone>0039.054428530</phone>
      <email>g.cruciani@ausl.ra.it</email>
    </contact>
    <investigator>
      <last_name>Giorgio Cruciani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Pietro Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Pavese, MD</last_name>
      <phone>0039.0633582831</phone>
      <email>idapavese@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Ida Pavese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pneumologia Oncologica II-San Camillo Forlanini Hospital</name>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica-San Camillo Forlanini Hopsital</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cora N Sternberg, MD</last_name>
      <phone>+39 0658704317</phone>
      <email>csternberg@scamilloforlanini.rm.it</email>
    </contact>
    <investigator>
      <last_name>Cora N Sternberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Cortesi, MD</last_name>
      <phone>+39 064462982</phone>
      <email>enricocortesi@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Cortesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Longo, MD</last_name>
      <phone>+39 0649970273</phone>
      <email>flavia.longo@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Flavia Longo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S. Giovanni - Addolorata Hospital</name>
      <address>
        <city>Roma</city>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Mauri, MD</last_name>
      <phone>+39 0677052929</phone>
      <email>mariella.mauri@libero.it</email>
    </contact>
    <investigator>
      <last_name>Maria Mauri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Giovanni di Dio e Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS. Annunziata</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Contu, MD</last_name>
      <phone>+39 0792061638</phone>
      <email>antoncontu@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Contu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita' di Sassari Oncologia Medica</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Farris, MD</last_name>
      <phone>0039.079228382</phone>
      <email>afarris@uniss.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Farris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Morelli</name>
      <address>
        <city>Sondrio</city>
        <zip>23035</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Valmadre, MD</last_name>
      <phone>0039.0342808322</phone>
      <email>giuseppe.valmadre@aovv.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Valmadre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sondrio Hospital-Azienda Ospedaliera Valtellina e Valchiavenna</name>
      <address>
        <city>Sondrio</city>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Bertolini, MD</last_name>
      <phone>+39 0342521594</phone>
      <email>abertolini@tiscalinet.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Bertolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Giovanni Battista Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libero Ciuffreda, MD</last_name>
      <phone>0039.0116334250</phone>
      <email>lciuffreda@molinette.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Libero Ciuffreda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>SS. Giovanni e Paolo Hospital</name>
      <address>
        <city>Venezia</city>
        <zip>30122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>San Bartolo Hospital</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Belcolle Hospital</name>
      <address>
        <city>Viterbo</city>
        <zip>01100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Moscetti, MD</last_name>
      <phone>+39 0761339040</phone>
      <email>l.moscetti@asl.vt.it</email>
    </contact>
    <investigator>
      <last_name>Luca Moscetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36. Erratum in: CA Cancer J Clin 2001 Mar-Apr;51(2):144.</citation>
    <PMID>11577478</PMID>
  </reference>
  <reference>
    <citation>Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.</citation>
    <PMID>11784875</PMID>
  </reference>
  <reference>
    <citation>Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000 May;18(10):2095-103.</citation>
    <PMID>10811675</PMID>
  </reference>
  <reference>
    <citation>Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005 Nov 20;23(33):8389-95.</citation>
    <PMID>16293869</PMID>
  </reference>
  <reference>
    <citation>Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97.</citation>
    <PMID>15117980</PMID>
  </reference>
  <reference>
    <citation>Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, SantabÃ¡rbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.</citation>
    <PMID>16014882</PMID>
  </reference>
  <reference>
    <citation>Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 1;23(25):5892-9. Epub 2005 Jul 25.</citation>
    <PMID>16043829</PMID>
  </reference>
  <reference>
    <citation>Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007 Apr 20;25(12):1545-52.</citation>
    <PMID>17442998</PMID>
  </reference>
  <reference>
    <citation>Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005 Feb 1;23(4):857-65.</citation>
    <PMID>15681531</PMID>
  </reference>
  <reference>
    <citation>Sequist LV, Joshi VA, JÃ¤nne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan;12(1):90-8.</citation>
    <PMID>17285735</PMID>
  </reference>
  <reference>
    <citation>Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005 Aug 15;11(16):5878-85.</citation>
    <PMID>16115929</PMID>
  </reference>
  <reference>
    <citation>van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S, Nederlof P. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol. 2007 Jan;18(1):99-103. Epub 2006 Oct 23.</citation>
    <PMID>17060486</PMID>
  </reference>
  <reference>
    <citation>Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005 May 4;97(9):643-55.</citation>
    <PMID>15870435</PMID>
  </reference>
  <reference>
    <citation>Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005 Nov 1;23(31):8081-92. Epub 2005 Oct 3.</citation>
    <PMID>16204011</PMID>
  </reference>
  <reference>
    <citation>Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 1;24(31):5034-42.</citation>
    <PMID>17075123</PMID>
  </reference>
  <reference>
    <citation>Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005 Aug 1;23(22):5007-18.</citation>
    <PMID>16051952</PMID>
  </reference>
  <reference>
    <citation>Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, CrinÃ² L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41.</citation>
    <PMID>15292385</PMID>
  </reference>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A(5):635-42.</citation>
    <PMID>8080679</PMID>
  </reference>
  <reference>
    <citation>Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J; Quality of Life Committee of the NCIC CTG. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2005 Jan;41(2):280-7.</citation>
    <PMID>15661554</PMID>
  </reference>
  <reference>
    <citation>Armstrong BG, Sloan M. Ordinal regression models for epidemiologic data. Am J Epidemiol. 1989 Jan;129(1):191-204.</citation>
    <PMID>2910061</PMID>
  </reference>
  <reference>
    <citation>CrinÃ² L; Zatloukal P; Reck M; Pesek M; Thomson J; Ford H; Hirsch F; Duffield E; Armour A; Cullen M. Gefitinib (Iressa) versus vinorelbine in chemonaive elderly pts with advanced NSCLC (INVITE): a randomized phase II study: B3-04. Journal of Thoracic Oncology Volume 2(8) Supplement 4 August 2007p S341 number 8</citation>
  </reference>
  <reference>
    <citation>Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011 May 20;29(15):2121-7. doi: 10.1200/JCO.2010.31.8923. Epub 2011 Apr 11.</citation>
    <PMID>21482992</PMID>
  </reference>
  <reference>
    <citation>Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.</citation>
    <PMID>21670455</PMID>
  </reference>
  <reference>
    <citation>Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, Shepherd FA, Leighl NB. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1805-11. doi: 10.1093/annonc/mdq682. Epub 2011 Jan 27.</citation>
    <PMID>21273345</PMID>
  </reference>
  <reference>
    <citation>Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010 Feb 10;28(5):744-52. doi: 10.1200/JCO.2009.24.3030. Epub 2009 Dec 28.</citation>
    <PMID>20038723</PMID>
  </reference>
  <reference>
    <citation>Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 Nov 22;372(9652):1809-18. doi: 10.1016/S0140-6736(08)61758-4.</citation>
    <PMID>19027483</PMID>
  </reference>
  <reference>
    <citation>Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010 Feb 15;16(4):1307-14. doi: 10.1158/1078-0432.CCR-09-1903. Epub 2010 Feb 9.</citation>
    <PMID>20145166</PMID>
  </reference>
  <reference>
    <citation>Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008 Sep 10;26(26):4244-52. doi: 10.1200/JCO.2007.15.0185.</citation>
    <PMID>18779611</PMID>
  </reference>
  <reference>
    <citation>Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.</citation>
    <PMID>19692680</PMID>
  </reference>
  <reference>
    <citation>Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, SzczÃ©sna A, JuhÃ¡sz E, Esteban E, Molinier O, Brugger W, MelezÃ­nek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.</citation>
    <PMID>20493771</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>February 23, 2012</last_update_submitted>
  <last_update_submitted_qc>February 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fatebenefratelli and Ophthalmic Hospital</investigator_affiliation>
    <investigator_full_name>Scanni Alberto</investigator_full_name>
    <investigator_title>Alberto Scanni MD</investigator_title>
  </responsible_party>
  <keyword>Advanced NSCLC</keyword>
  <keyword>EGFR</keyword>
  <keyword>EGFR copy number</keyword>
  <keyword>Kras mutations</keyword>
  <keyword>EGRF mutations</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Polymorphisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

